Dashboard
Manage Tickers

VERUVERU INC.

Nasdaq verupharma.com


$ 1.39 $ -0.07 (-4.79 %)    

Thursday, 09-May-2024 14:12:26 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 440.79 $ 0.28 (0.06 %)
DIA $ 393.14 $ 3.06 (0.78 %)
SPY $ 519.18 $ 1.74 (0.34 %)
TLT $ 90.58 $ 0.54 (0.6 %)
GLD $ 216.08 $ 1.38 (0.64 %)
$ 1.43
$ 1.46
$ 1.38 x 800
$ 1.40 x 100
$ 1.36 - $ 1.47
$ 0.36 - $ 1.92
3,313,229
na
209.33M
$ 0.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-Q
3 12-08-2023 09-30-2023 10-K
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-09-2023 12-31-2022 10-Q
7 12-05-2022 09-30-2022 10-K
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-Q
11 12-02-2021 09-30-2021 10-K
12 08-12-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 02-10-2021 12-31-2020 10-Q
15 12-10-2020 09-30-2020 10-K
16 08-13-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 02-12-2020 12-31-2019 10-Q
19 12-12-2019 09-30-2019 10-K
20 08-08-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 02-13-2019 12-31-2018 10-Q
23 12-13-2018 09-30-2018 10-K
24 08-14-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-Q
27 01-02-2018 09-30-2017 10-K
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-Q
31 12-12-2016 09-30-2016 10-K
32 07-28-2016 06-30-2016 10-Q
33 04-28-2016 03-31-2016 10-Q
34 02-02-2016 12-31-2015 10-Q
35 12-02-2015 09-30-2015 10-K
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-03-2015 12-31-2014 10-Q
39 12-02-2014 09-30-2014 10-K
40 07-31-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

veru-q2-2024-adj-eps-007-misses-005-estimate-sales-410m-beat-300m-estimate
Veru Q2 2024 Adj EPS $(0.07) Misses $(0.05...
05/08/2024 10:33:16

Veru (NASDAQ:VERU) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 ...

critical-insights-from-veru-analyst-ratings-what-you-need-to-know
Critical Insights From Veru Analyst Rating...
05/06/2024 13:01:00

hc-wainwright--co-maintains-buy-on-veru-raises-price-target-to-3
HC Wainwright & Co. Maintains Buy on Veru,...
05/06/2024 09:33:38

HC Wainwright & Co. analyst Yi Chen maintains Veru (NASDAQ:VERU) with a Buy and raises the price target from $2 to $3.

veru-to-present-at-the-glp-1-based-therapeutics-summit
Veru To Present At The GLP-1 Based Therape...
05/02/2024 12:38:21

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserv...

veru-enrolls-first-patients-in-phase-2b-clinical-trial-of-enobosarm-and-semaglutide-combination-for-weight-loss
Veru Enrolls First Patients In Phase 2b Cl...
04/30/2024 12:31:58

why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Ultragenyx Pharmaceutical Shares Are T...
04/15/2024 18:11:35

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

cisco-to-rally-around-24-here-are-10-top-analyst-forecasts-for-monday
Cisco To Rally Around 24%? Here Are 10 Top...
04/15/2024 12:39:51

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

oppenheimer-reiterates-outperform-on-veru-lowers-price-target-to-5
Oppenheimer Reiterates Outperform on Veru,...
04/15/2024 11:55:16

Oppenheimer analyst Leland Gershell reiterates Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $7 to $5.

why-jpmorgan-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-fridays-mid-day-session
Why JPMorgan Shares Are Trading Lower By A...
04/12/2024 18:47:23

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

12-consumer-staples-stocks-moving-in-tuesdays-after-market-session
12 Consumer Staples Stocks Moving In Tuesd...
04/09/2024 20:31:12

raymond-james-initiates-coverage-on-veru-with-outperform-rating-announces-price-target-of-3
Raymond James Initiates Coverage On Veru w...
03/28/2024 10:10:15

Raymond James analyst Gary Nachman initiates coverage on Veru (NASDAQ:VERU) with a Outperform rating and announces Price Tar...

watching-veru-traders-circulate-analyst-comments-suggesting-co-could-see-a-take-out-from-large-pharma-due-to-effectivr-glp-1-gives-it-an-outperform-rating-and-3-pt
Watching Veru; Traders Circulate Analyst C...
03/27/2024 20:14:14

reported-earlier-veru-receives-nasdaq-notice-for-delay-in-filing-quarterly-report
Reported Earlier, Veru Receives Nasdaq Not...
02/28/2024 07:22:29

hc-wainwright--co-reiterates-buy-on-veru-maintains-2-price-target
HC Wainwright & Co. Reiterates Buy on Veru...
02/08/2024 20:25:11

HC Wainwright & Co. analyst Yi Chen reiterates Veru (NASDAQ:VERU) with a Buy and maintains $2 price target.

veru-q1-sales-210m-miss-520m-estimate
Veru Q1 Sales $2.10M Miss $5.20M Estimate
02/08/2024 11:32:23

Veru (NASDAQ:VERU) reported quarterly sales of $2.10 million which missed the analyst consensus estimate of $5.20 million by 59...

earnings-scheduled-for-february-8-2024
Earnings Scheduled For February 8, 2024
02/08/2024 09:43:03

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share ...

8-consumer-staples-stocks-moving-in-tuesdays-intraday-session
8 Consumer Staples Stocks Moving In Tuesda...
02/06/2024 17:31:34

veru-announces-fda-clearance-of-ind-application-for-phase-2b-clinical-trial-with-enobosarm-to-treat-muscle-loss-associated-with-weight-loss-drugs
Veru Announces FDA Clearance Of IND Applic...
02/06/2024 13:31:41

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially ...

veru-submits-ind-application-to-fda-for-development-of-enobosarm-to-prevent-muscle-loss-while-augmenting-fat-loss-in-combination-with-glp-1-drugs-for-weight-loss
Veru Submits IND Application To FDA For De...
01/08/2024 13:38:20

veru-inc-13g-filing-shows-adage-capital-partners-lp-reported-a-95-stake-in-the-co-as-of-december-14-2023
Veru Inc. 13G Filing Shows Adage Capital P...
12/26/2023 21:40:53

- SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION